Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
Allogene Therapeutics Announces Preliminary Safety, Efficacy And Translational Data From Its Phase 1 RESOLUTION Trial Of ALLO-329 At American College Of Rheumatology
Allogene (ALLO) Q3 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. (ALLO) Q3 2026 Earnings Call Transcript
Allogene Therapeutics Inc (ALLO) (Q3 2026) Earnings Call Highlights: Alpha 3 Momentum Builds as ...
Allogene Therapeutics Q3 Earnings Call Highlights
Allogene Therapeutics: Q3 Earnings Snapshot
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Allogene Therapeutics Q3 2026 Earnings Call Transcript
Allogene Therapeutics Q3 EPS $(0.15), Inline
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Allogene: If MRD Holds, This Becomes A Completely Different Company
Allogene Therapeutics EVP And CFO Geoffrey Parker To Retire, Effective November 6
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.